EKR Therapeutics, Inc., an emerging specialty pharmaceutical company, has completed its first institutional financing led by NewSpring Capital and ESP Equity Partners. EKR will be led by Howard Weisman, former founder, President and Director of ESP
Pharma, formed in 2002 and sold to PDL BioPharma for over $500 million. Mr. Weisman,
Chairman and CEO of the company, is joined by EKR co-founders Cathy Kerzner and
Richard DeSimone, who will serve as President and Chief Financial Officer, respectively.
Genetic Engineering News